New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
08:11 EDTCGIXCancer Genetics launches CALR mutation analysis test
Cancer Genetics has launched a genetic diagnostic test for detecting mutations in the calreticulin gene. This test helps physicians identify patients with certain types of myeloproliferative neoplasms, which are blood cancers that have the potential to evolve into acute leukemia. CGI is one of the first laboratories in the U.S. to offer this test under both CLIA and NY-State Approvals. Patients with the CALR mutation are understood to have more favorable disease outcomes as well as longer overall survival in comparison to patients who possess other biomarkers. Therefore, the results of the test could have implications in predicting a patient's outlook.
News For CGIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2015
08:02 EDTCGIXCancer Genetics suspends active on 'at-the-market' equity
Cancer Genetics announced that it has suspended activity on the sale of shares through an "at-the-market" offering.
08:02 EDTCGIXCancer Genetics suspends at-the-market equity offering
July 23, 2015
07:31 EDTCGIXRedChip to hold a virtual conference
2015 Global Online CEO Conference is being held on July 22-23 with webcasted presentations to begin on July 23 at 9:30 am. Webcast Link
July 22, 2015
07:20 EDTCGIXRedChip to hold a virtual conference
Subscribe for More Information
July 16, 2015
07:04 EDTCGIXCancer Genetics announces agreement with HPHC
Cancer Genetics announced that it has signed an agreement with Harvard Pilgrim Healthcare, or HPHC, a health care network covering over 1M people throughout Massachusetts, Connecticut and Maine. Under the terms of the agreement, CGI will offer cancer diagnostic services to individuals covered under Harvard Pilgrim plans. Harvard Pilgrim's extensive provider network includes over 135 hospitals and 28,000 doctors and clinicians among them, physicians who practice in a variety of settings, including individual practices, small medical groups and large multi-specialty groups. As part of the agreement, the HPHC network will have access to the full range of oncology-focused proprietary tests offered by CGI. Working with provider networks, such as Harvard Pilgrim Healthcare, is central to CGI's multi-part access and reimbursement strategy. By establishing relationships with leading payers and insurance companies, CGI plans to expand access to and ensure reimbursement for the Company's leading-edge genomic tests to help providers appropriately manage and personalize treatment.
06:12 EDTCGIXCancer Genetics enters $20M controlled equity offering sales agreement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use